(Q54134260)

English

Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/MED/9635235

Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. (English)

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/MED/9635235

0 references

1

object named as

Jones RN

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/MED/9635235

Jerome J. Schentag

5

object named as

Schentag JJ

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/MED/9635235

author name string

Ballow CH

2

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/MED/9635235

Biedenbach DJ

3

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/MED/9635235

Deinhart JA

4

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/MED/9635235

publication date

1 July 1998

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/MED/9635235

Diagnostic Microbiology and Infectious Disease

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/MED/9635235

31

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/MED/9635235

437-451

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/MED/9635235

3

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/MED/9635235

RP 59500, a new streptogramin highly active against recent isolates of North American staphylococci

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of glycopeptide resistance in enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Provisional interpretive criteria for quinupristin/dalfopristin susceptibility tests

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative in-vitro activity of quinupristin/dalfopristin (RP 59500) tested against penicillin-and macrolide-resistant pneumococci by the Etest

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative in vitro activity of quinupristin/dalfopristin against multidrug resistant Enterococcus faecium

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Trends in gram-positive bloodstream organism resistance: a seven-year audit of five glycopeptides and other drugs at a large university hospital.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro susceptibilities of clinical isolates of vancomycin-resistant enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The in-vitro activity of RP 59500 against gram-positive cocci

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Antimicrobial characteristics of quinupristin/dalfopristin (Synercid at 30:70 ratio) compared to alternative ratios for in vitro testing

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activity of RP 59500 (quinupristin/dalfopristin) against antibiotic-resistant strains of Streptococcus pneumoniae and enterococci.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Antimicrobial Activity of SCH 27899, Oligosaccharide Member of the Everninomycin Class with a Wide Gram-Positive Spectrum.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Nosocomial enterococcal blood stream infections in the SCOPE program: Antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidemiology, control and treatment of multiresistant pneumococci

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of infections due to resistant enterococci: a review of therapeutic options

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Streptogramins. A unique class of antibiotics.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification of the satA gene encoding a streptogramin A acetyltransferase in Enterococcus faecium BM4145.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of Vitek and API 20S for species identification of enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Emergence of vancomycin resistance in coagulase-negative staphylococci

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanism of action of streptogramins and macrolides

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative in-vitro activity of RP 59500

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The worldwide prevalence of methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Current perspectives on glycopeptide resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2980002-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0732-8893(98)80002-3

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/MED/9635235

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/MED/9635235

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54134260&oldid=2143568441"